Skip to content

Effect of Non-pharmacological Therapy on Cognitive Function of Patients With Cognitive Impairment

Effect of Non-pharmacological Therapy on Cognitive Function of Patients With Cognitive Impairment

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01819623
Enrollment
0
Registered
2013-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2015-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Keywords

Mild Cognitive Impairment, Cognitive training

Brief summary

Supervised nonpharmacologic therapy improve cognitive function in patients with Mild Cognitive Impairment

Interventions

It consists of a weekly two-hour session. During the first hour yoga classes will taught by teacher, during second hour supervised cognitive training by a psychologist based on Memory Program designed by Memory Unit of Madrid

Sponsors

National Institute of Medical Sciences and Nutrition, Salvador Zubiran
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients 60 years and older with Mild Cognitive Impairment according to Petersen Criteria * Phone number available

Exclusion criteria

* Untreated depression * Evidence of a reversible cause of cognitive decline * Dementia of any type and stage * Severe sensory deficit unresolved * Metastatic cancer * Hemoglobin level \< 8g/dL * Chronic Obstructive Pulmonary Disease Gold stage 3 or 4 * Congestive Heart Failure decompensated, unstable angina o Functional Class IV according to New York Heart Association * Participation in another protocol that prevents its participation in this research * Chronic use of benzodiazepines, tricyclic antidepressants * Patients whose place of residence can not attend the sessions

Design outcomes

Primary

MeasureTime frameDescription
Cognitive functionsix monthsCognitive function measured by Alzheimer's Disease Assessment Cognitive Scale (ADAS-Cog) sum of boxes after non-pharmacological intervention for six months.

Secondary

MeasureTime frameDescription
Cognitive function six months after completing interventionone yearCognitive function measured by Alzheimer's Disease Assessment Cognitive Scale (ADAS-Cog) six months after completing intervention
Depressive symptomssix monthsDepressive symptoms measured by Geriatric Depression Scale (GDS) before and after intervention period

Other

MeasureTime frameDescription
quality of lifesix monthsQuality of life measured by a scale validated in Spanish before and after intervention period

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026